High HER2/Centromeric Probe for Chromosome 17 Fluorescence in Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer

Oncologist - United States
doi 10.1634/theoncologist.2015-0101
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Related search

Prognostic Value of HER2 to CEP17 Ratio on Fluorescence in Situ Hybridization Ratio in Patients With Nonmetastatic HER2‐Positive Inflammatory and Noninflammatory Breast Cancer Treated With Neoadjuvant Chemotherapy With or Without Trastuzumab

Oncologist
Cancer ResearchMedicineOncology
2020English

Effectiveness of Neoadjuvant Trastuzumab and Chemotherapy in HER2-overexpressing Breast Cancer

Journal of Cancer Research and Clinical Oncology
MedicineCancer ResearchOncology
2013English

Prolonged Survival of Patients Receiving Trastuzumab Beyond Disease Progression for HER2 Overexpressing Metastatic Breast Cancer (MBC)

Oncology Research and Treatment
Cancer ResearchOncologyHematology
2005English

Complete Pathological Response in Patients With Locally Advanced Cancer of Breast and Positive Her2/Neu With Neoadjuvant Chemotherapy

BMC Cancer
Cancer ResearchOncologyGenetics
2007English

T-Bet Expression in Intratumoral Lymphoid Structures After Neoadjuvant Trastuzumab Plus Docetaxel for HER2-overexpressing Breast Carcinoma Predicts Survival

British Journal of Cancer
Cancer ResearchOncology
2011English

Complete Response in HER2+ Leptomeningeal Carcinomatosis From Breast Cancer With Intrathecal Trastuzumab

Breast Cancer Research and Treatment
Cancer ResearchOncology
2011English

Dynamic Changes in CD44v-positive Cells After Preoperative Anti-Her2 Therapy and Its Correlation With Pathologic Complete Response in HER2-positive Breast Cancer

Oncotarget
Oncology
2018English

Efficacy of Neoadjuvant Therapy With Trastuzumab Concurrent With Anthracycline- And Nonanthracycline-Based Regimens for HER2-positive Breast Cancer

Cancer
Cancer ResearchOncology
2011English

Anti-Her2 CD4+ T-Helper Type 1 Response Is a Novel Immune Correlate to Pathologic Response Following Neoadjuvant Therapy in HER2-positive Breast Cancer

Breast Cancer Research
Cancer ResearchOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy